COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer

Phase 2 Unknown 36 enrolled Sun Yat-sen University

NaSingle-groupOpen-labelTreatment

Summary

The study is a single-arm, phase II trial. The purpose is to investigate both the efficacy and safety of radiotherapy combined with anti-PD-1 antibody in unresectable biliary tract cancer patients.

Timeline

Start: 2019-12-10
Primary completion: 2024-11
Completion: 2024-11

Outcome

Met primary endpoint

paper External radiotherapy plus camrelizumab, as first-line therapy, met its primary endpoint PMID 38637772 ↗

Publications

Zhu M, Jin M, Zhao X, Shen S, Chen Y, Xiao H, Wei G, He Q, Li B, Peng Z. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma. BMC Med. 2024 Apr 19;22(1):165. doi: 10.1186/s12916-024-03381-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous